Blood Pressure Drug Telmisartan Shows Promise in Boosting Cancer Therapy Effectiveness
A groundbreaking study led by Dr. Tyler J. Curiel at the Dartmouth Cancer Center (DCC) reveals that telmisartan, an FDA-approved blood pressure medication, can significantly enhance the effectiveness of olaparib, a targeted cancer therapy. Published in The Journal for ImmunoTherapy of Cancer, the research suggests a potential expansion of olaparib’s use to a broader patient population.
PARP Inhibitors and the Challenge of Resistance
PARP inhibitors like olaparib target cancers with defects in DNA repair mechanisms, particularly those with BRCA gene mutations. Still, many tumors lack these defects, limiting the drug’s applicability. Cancers often develop resistance to PARP inhibitors over time. Dr. Curiel’s team discovered that telmisartan can overcome these limitations, making tumors more susceptible to PARP inhibitors even without the typical DNA repair deficiencies.
How Telmisartan Enhances Cancer Treatment
Preclinical studies demonstrated that combining telmisartan with olaparib increased DNA damage in tumor cells and triggered a robust immune response. Specifically, the combination boosted the production of type I interferons, signaling molecules that alert the immune system to the presence of cancer. “This immune activation appears to be a key reason the combination works so well,” explained Dr. Curiel.
Telmisartan: A Unique Advantage Among Blood Pressure Medications
The DCC study highlighted that the cancer-enhancing effects were specific to telmisartan among the angiotensin II receptor blocker (ARB) class of drugs. Telmisartan also reduced levels of PD-L1, a protein cancers use to evade immune detection, further amplifying its therapeutic potential.
“Telmisartan has several distinct anticancer effects that, together with targeted therapy, could make tumors more responsive to distinct types of treatments,” Dr. Curiel stated. He also noted that data suggests telmisartan improves the efficacy of various chemotherapy classes and immunotherapies in multiple cancer types through similar mechanisms.
Clinical Trials Underway
Telmisartan’s oral bioavailability, safety profile, and tolerability – even in individuals without hypertension – make it an ideal candidate for clinical translation. Dr. Curiel and his team at DCC are currently evaluating the combination in two ongoing clinical trials.
One trial focuses on men with metastatic, castration-resistant prostate cancer, with initial results showing an “exceptional response” in the first patient enrolled. The second trial is investigating the combination in patients with platinum-resistant ovarian cancer.
“We are encouraged by what we are seeing so far,” Dr. Curiel said. “Our goal is to determine whether this combination approach can help more patients benefit from greater effectiveness of PARP inhibitors and other cancer treatment classes and potentially overcome resistance to these drugs.”
Future Trends and Implications
The success of telmisartan in preclinical and early clinical trials points towards a broader trend: repurposing existing, well-characterized drugs for cancer treatment. This approach offers several advantages, including reduced development time and cost compared to developing entirely new drugs. The focus on modulating the tumor microenvironment and stimulating the immune system, as demonstrated by telmisartan, is also gaining prominence in cancer research.
The Rise of Immunotherapy Combinations
Combining PARP inhibitors with immunotherapies, potentially enhanced by drugs like telmisartan, represents a promising avenue for future cancer treatment. The ability to overcome resistance and broaden the patient population who can benefit from these therapies is crucial. Further research will likely explore other blood pressure medications and their potential immunomodulatory effects in the context of cancer.
Personalized Medicine and Biomarker Identification
Identifying biomarkers that predict which patients are most likely to respond to the telmisartan-olaparib combination will be essential for personalized medicine approaches. This could involve analyzing genetic profiles, immune cell populations, and PD-L1 expression levels.
FAQ
Q: What is telmisartan?
A: Telmisartan is an FDA-approved medication commonly used to treat high blood pressure.
Q: How does telmisartan function with olaparib?
A: Telmisartan appears to enhance the cancer-killing activity of olaparib by increasing DNA damage in tumor cells and boosting the immune response.
Q: Is telmisartan safe for people without high blood pressure?
A: Telmisartan is generally well-tolerated, and the clinical trials are evaluating its use even in individuals without hypertension.
Q: Where can I find more information about the clinical trials?
A: Information about the clinical trials can be found through the Dartmouth Cancer Center website.
Did you know? The Curiel Lab has been continuously funded by the NIH since 1987, demonstrating a long-standing commitment to cancer research.
Pro Tip: Discuss any potential medication changes with your healthcare provider before starting or stopping any treatment.
Stay informed about the latest advancements in cancer research. Explore more articles on cancer treatment and prevention on our website.
